NCT03696212 2021-02-21Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaArrys TherapeuticsPhase 1/2 Terminated18 enrolled
NCT02538432 2019-11-04Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid TumorsUniversity of Maryland, BaltimorePhase 2 Withdrawn